Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.33
+0.10 (0.79%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Enanta Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 34.93 | 32.3 | 37.23 | 85.39 | 43.99 | 57.21 |
Short-Term Investments | 128.85 | 156.57 | 210.95 | 284.52 | 205.24 | 186.8 |
Cash & Short-Term Investments | 163.77 | 188.86 | 248.19 | 369.91 | 249.23 | 244 |
Cash Growth | -15.31% | -23.90% | -32.91% | 48.42% | 2.14% | -36.89% |
Accounts Receivable | 7.81 | 6.88 | 6.65 | 8.61 | 20.32 | 23.58 |
Other Current Assets | 6.83 | 8.59 | 44.62 | 44.27 | 42.16 | 51.44 |
Total Current Assets | 178.41 | 204.34 | 299.45 | 422.79 | 311.71 | 319.02 |
Net Property, Plant & Equipment | 69.55 | 72.94 | 73.35 | 34.71 | 29.75 | 10.65 |
Long-Term Investments | 63.24 | - | - | - | 29.29 | 108.42 |
Other Long-Term Assets | 3.5 | 3.45 | 3.45 | 4.77 | 4.66 | 0.7 |
Total Assets | 314.7 | 280.73 | 376.25 | 462.28 | 375.41 | 438.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 4.36 | 1.95 | 8 | 4.1 | 6 | 9.54 |
Accrued Expenses | 6.86 | 12.75 | 13.55 | 18.34 | 20.94 | 22.43 |
Current Portion of Leases | 3.76 | 3.15 | 1.52 | 5.28 | 2.89 | 4.2 |
Other Current Liabilities | 31.46 | 30.71 | 34.46 | 35.08 | - | - |
Total Current Liabilities | 46.44 | 48.56 | 57.54 | 62.79 | 29.83 | 36.17 |
Long-Term Leases | 52.78 | 54.76 | 53.94 | 21.24 | 22.37 | 1.13 |
Other Long-Term Liabilities | 98.9 | 112.68 | 136.36 | 161.52 | 1.88 | 2.06 |
Total Long-Term Liabilities | 151.68 | 167.44 | 190.3 | 182.75 | 24.25 | 3.19 |
Total Liabilities | 198.12 | 216.02 | 247.84 | 245.54 | 54.08 | 39.36 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 0.29 | 0.21 | 0.21 | 0.21 | 0.21 | 0.2 |
Additional Paid-in Capital | 546.99 | 469.77 | 451.34 | 424.69 | 398.03 | 351.03 |
Accumulated Other Comprehensive Income | -0.73 | -0.34 | 0.3 | -1.17 | -3.72 | -0.38 |
Retained Earnings | -429.96 | -404.93 | -323.04 | -207 | -73.18 | 48.58 |
Shareholders' Equity | 116.59 | 64.72 | 128.81 | 216.74 | 321.33 | 399.43 |
Total Liabilities & Equity | 314.7 | 280.73 | 376.65 | 462.28 | 375.41 | 438.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 56.54 | 57.9 | 55.47 | 26.51 | 25.26 | 5.33 |
Net Cash (Debt) | 107.24 | 130.96 | 192.72 | 343.4 | 223.97 | 238.67 |
Net Cash Growth | -20.35% | -32.05% | -43.88% | 53.32% | -6.16% | -36.95% |
Net Cash Per Share | 4.27 | 6.14 | 9.11 | 16.38 | 10.87 | 11.83 |
Book Value | 116.59 | 64.72 | 128.81 | 216.74 | 321.33 | 399.43 |
Book Value Per Share | 4.64 | 3.03 | 6.09 | 10.34 | 15.60 | 19.80 |
Tangible Book Value | 116.59 | 64.72 | 128.81 | 216.74 | 321.33 | 399.43 |
Tangible Book Value Per Share | 4.64 | 3.03 | 6.09 | 10.34 | 15.60 | 19.80 |